Navigation Links
Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting
Date:10/20/2009

WALTHAM, Mass., Oct. 20 /PRNewswire-USNewswire/ -- Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

LT-NS001 is the first in a new class of bio-activated pro-drugs. It is a novel, patented new chemical entity (NCE) pro-drug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed by Logical Therapeutics to significantly reduce the gastrointestinal (GI) safety risks, including the formation of ulcers, associated with naproxen.

"We are very encouraged by the results of the LT-NS001 vs. naproxen study, and we look forward to sharing them later this month at the ACG meeting," said Peter A. Lankau, chief executive officer of Logical Therapeutics. "This novel, bio-activated pro-drug is being developed to fulfill an unmet need in the marketplace - to provide a single agent capable of delivering relief to those who suffer from chronic inflammatory conditions like arthritis, while significantly improving the GI safety and tolerability as compared to naproxen."

LT-NS001 Well-Tolerated with No Serious Adverse Events

LT-NS001 is unique among NSAIDs as it is pharmacologically inactive as a Cox inhibitor in the GI tract, but once absorbed into the bloodstream, it is converted rapidly and quantitatively to naproxen. In previous clinical studies, LT-NS001 was well-tolerated with no serious adverse events. In pre-clinical testing, LT-NS001 demonstrated significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety prof
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma
2. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
3. Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
4. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
5. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
6. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
7. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
8. Genetic Research Leads to New Discovery in Understanding Rare Neurological Disorder
9. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
10. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
11. The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Countrys Biological Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Nov. 28, 2014 /CNW Telbec/ - Ergoresearch Ltd « Ergoresearch ... of Mrs. Dominique Boudreau who will hold ... Mrs. Dominique Boudreau was acting as corporate ... similar duties for more than seven years for Laboratoire ... January 2013.  Mrs. Boudreau replaces Mr. Greco who was ...
(Date:11/28/2014)... Kan. , Nov. 28, 2014 Aratana ... company focused on the licensing or acquisition, development and ... other companion animals, today announced that it will present ... Conference, to be held December 2-3, 2014, at the ... . Steven St. Peter , ...
(Date:11/28/2014)... 28, 2014 Alimera Sciences, Inc. (NASDAQ: ... that specializes in the research, development and commercialization ... Securities Purchase Agreement with Deerfield Management and certain ... will issue shares of preferred stock to Deerfield ... million upon the satisfaction of certain closing conditions. ...
Breaking Medicine Technology:Ergoresearch announces the appointment of its new Vice Président Finance 2Ergoresearch announces the appointment of its new Vice Président Finance 3Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3
... 5, 2011 Mylan Inc. (Nasdaq: MYL ) today ... of the NASDAQ OMX Group Inc. (Nasdaq: NDAQ ), ... due 2012 from the Nasdaq Capital Market, on which the notes ... of trading on January 28, 2011. The notes will continue to ...
... and older falls every 2.3 seconds in the U.S., and according ... cause of fatal injury in this age group. They are ... for trauma.  The growing ranks of Americans 65 and older - ... 2050 - have inspired a new technology solution that allows the ...
Cached Medicine Technology:Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq 2SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011 2SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011 3
(Date:11/28/2014)... Miami's Plastic Surgery of the Face recently introduced ... Jeffrey Epstein is excited to offer patients the ... the site is uniquely designed for easing viewing on ... of all prospective rhinoplasty patients research upcoming procedures online. ... with smartphones, tablets, and laptops, as well as the ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Written and narrated ... Brook Forest Voices releases the “The Happiest Man In ... a compelling account of how and why Project C.U.R.E. came ... by his mother Josie and the Reverend Richard W. Jackson, ... the age of 30, but realized that he wasn’t happy. ...
(Date:11/28/2014)... Not only is the Éminence Organic ... petroleum, parabens and other cancer-causing agents, but they are ... and awareness programs that help in the fight against ... raised an incredible, record-breaking contribution of $30,000 through participation ... the Sweet Red Rose Whip Moisturizer and the company’s ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Mabel’s ... stuff kids lose® and an award-winning company established by ... Ellis, Cynthia Esp, and Tricia Mumby have been honored ... were recognized with the PROFIT Award for Excellence in ... Cynthia Esp, and Tricia Mumby) accepted the award on ...
(Date:11/28/2014)... Lice Troopers Lice Removal Service is pleased to ... lice service for moms in Miami-Dade County. Lice Troopers is ... on Pone De-leon Blvd in Miami. The company currently ... Miami-Dade & Broward. Lice Troopers is the only Lice Clinic ... been treating families for several years. , Lice Troopers estimate ...
Breaking Medicine News(10 mins):Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2
... ... for dentists with advanced clinical training announced. , ... Seattle, WA (PRWEB) June 23, 2009 -- Big Case Marketing, the global ... for large cases and Dental Idea Lab, a Boston based coaching and consulting firm for ...
... ... and FIND (Foundation for Innovative New Diagnostics), a Swiss foundation that develops, evaluates and ... price reduction in the cost of liquid culture testing for TB (Tuberculosis). , ... Oxford, UK and Geneva, ...
... SAN DIEGO, June 22 CetylMax, LLC and Flexadren, ... Cetylated Fatty Acids (CFA,s) products aiding in joint support ... Board: IAGX), the manufacturer of Celadrin, did not prevail ... the nature and outcome of the Federal litigation between ...
... inhibitor of tumor metastasis made by tumor cells, one that ... were published in the online Early Edition of the ... week of June 22. Metastasisthe migration of cancer ... leading causes of death from cancer, and there is no ...
... WASHINGTON, June 22 The Lupus Foundation of America ... studies on lupus, an unpredictable and potentially fatal autoimmune ... lupus and adult stem cell transplantation. The purposes of ... research in humans as a treatment for lupus and ...
... , , Personalized Medicine Meeting Elicits Varying Perspectives ... Drug Administration,s (FDA,s) ability to regulate genetic testing is problematic, ... , Three-quarters of the attendees at a colloquium ... Institute (FDLI) and the American Association for the Advancement of ...
Cached Medicine News:Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 3Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 2Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 3Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 4Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 2Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 3Health News:Potent metastasis inhibitor identified 2Health News:Lupus Foundation of America Seeks Proposals for Research Studies on Childhood Lupus and Stem Cell Transplantation 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 3
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Diameter; 5.4 Fr Straight Channel; 33 or ... MRO-7 Integral Operating Ureteroscopes offer a small ... easy access to the ureter for diagnosis ... Fr) is ideal for large operating instruments, ...
Semi-Rigid Ureteroscope...
... ACMI DUR-8 Elite's 8.7 Fr shaft reaches ... comparable scope providing complete intrarenal access, ... smooth, lubricious outer covering and working channel ... And its patented torque-stable shaft construction, tight-bend ...
Medicine Products: